Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-485-8080
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.14 million
Profitability
Miscellaneous
Employees58
Next Earnings Date3/26/2019 (Estimated)
OptionableNot Optionable
Novan (NASDAQ:NOVN) Frequently Asked Questions
What is Novan's stock symbol?
Novan trades on the NASDAQ under the ticker symbol "NOVN."
How were Novan's earnings last quarter?
Novan Inc (NASDAQ:NOVN) issued its earnings results on Friday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The firm earned $0.10 million during the quarter, compared to analyst estimates of $10.80 million. Novan had a negative net margin of 1,087.54% and a negative return on equity of 999.64%. View Novan's Earnings History.
When is Novan's next earnings date?
What price target have analysts set for NOVN?
3 analysts have issued twelve-month price objectives for Novan's shares. Their predictions range from $6.00 to $14.00. On average, they anticipate Novan's share price to reach $8.6667 in the next twelve months. This suggests a possible upside of 499.6% from the stock's current price. View Analyst Price Targets for Novan.
What is the consensus analysts' recommendation for Novan?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novan.
What are Wall Street analysts saying about Novan stock?
Here are some recent quotes from research analysts about Novan stock:
- 1. According to Zacks Investment Research, "Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through Nitricil technology(TM). Novan, Inc. is based in Durham, United States. " (2/12/2019)
- 2. HC Wainwright analysts commented, "We eagerly anticipate, any day now, data from the Phase 2 dose-ranging study of SB206—topical nitric oxide (NO) gel—for molluscum contagiosum. We see molluscum as a large, underserved pediatric dermatology opportunity, with no FDA approved Rx treatments, and it is currently the key contributor to our Novan valuation. If Phase 2 is positive, with SB206 demonstrating meaningful molluscum lesion clearance rates at 12-weeks and good tolerability, it should be a transformational catalyst for Novan. Note that the only molluscum comparable, Verrica Pharmaceuticals (VRCA; not rated), which has positive open-label molluscum Phase 2 data and Phase 3 expected in 1Q19, has a $350M market cap—dramatically higher than Novan’s current $68M market cap." (11/6/2018)
Has Novan been receiving favorable news coverage?
News articles about NOVN stock have been trending positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novan earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Novan's key competitors?
Some companies that are related to Novan include CytoDyn (CYDY), Neos Therapeutics (NEOS), Aquestive Therapeutics (AQST), AgeX Therapeutics (AGE), Aptinyx (APTX), BioXcel Therapeutics (BTAI), Newron Pharmaceuticals (NWPHF), Sierra Oncology (SRRA), China SXT Pharmaceuticals (SXTC), Eton Pharmaceuticals (ETON), ASLAN PHARMACEU/ADR (ASLN), Unum Therapeutics (UMRX), Chiasma (CHMA), Harrow Health (HROW) and Sol Gel Technologies (SLGL).
What other stocks do shareholders of Novan own?
Who are Novan's key executives?
Novan's management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 60)
- Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
- Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
- Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
- Mr. Andrew J. Novak, VP & Chief Accounting Officer
When did Novan IPO?
(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Novan's major shareholders?
Novan's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include CVI Holdings LLC (0.72%), RMB Capital Management LLC (0.12%) and Bank of New York Mellon Corp (0.11%). Company insiders that own Novan stock include G Kelly Martin, John W Palmour and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.
Which major investors are selling Novan stock?
Which major investors are buying Novan stock?
NOVN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and RMB Capital Management LLC. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John W Palmour and Robert Alexander Ingram. View Insider Buying and Selling for Novan.
How do I buy shares of Novan?
Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novan's stock price today?
One share of NOVN stock can currently be purchased for approximately $1.4453.
How big of a company is Novan?
Novan has a market capitalization of $37.66 million and generates $2.14 million in revenue each year. The company earns $-37,120,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Novan employs 58 workers across the globe.
What is Novan's official website?
How can I contact Novan?
Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]
MarketBeat Community Rating for Novan (NASDAQ NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
